Mr. Michael Farley reports

SOLARVEST ANNOUNCES MANAGEMENT CHANGES

Solarvest Bioenergy Inc. has appointed Michael Farley as president of the company effective immediately following the resignation of Claes Ellegaard, who has agreed to tender his resignation.

Mr. Farley is an entrepreneur and corporate, business adviser to health and wellness companies in international markets. Dr. Farley was involved in dozens of financial, market entry, and M&A (merger and acquisition) transactions since the early 2000s. He is also partnered with a corporate advisory firm in Switzerland offering IR services to NA life science small caps in Europe. In the 1990s, Mr. Farley managed technology and investment programs at the Canadian Foreign Affairs Department. He holds a PhD in the philosophy of science from the Universite de Montreal.

Solarvest is also pleased to announce that Garth Greenham has been appointed as chief operating officer of the company effective Oct. 31, 2023.

Mr. Greenham is an executive of the company and a corporate director with an extensive record with both privately held and publicly traded health care companies. He served as president of the global aquaculture division of Novartis Inc. He started his career with Johnson & Johnson (J&J) where he served 15 years mostly with McNeil Pharmaceutical in numerous management positions in operations and contract and export sales. He joined Cobequid Life Sciences Inc. (KQR) and served as director of sales, marketing and operations for nine years, and helped grow the company to global leader in the field of aquaculture animal vaccines.

The company would like to thank Mr. Ellegaard for his tenure during challenging times for the company.

About Solarvest Bioenergy Inc.

Solarvest Bioenergy is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins.

We seek Safe Harbor.